Dydrogesterone Global Buyers List: A Strategic Guide for Pharmaceutical Procurement

Dydrogesterone, a synthetic progestogen with a molecular formula of C₂₁H₂₈O₂ and CAS number 152-62-5, has become a cornerstone in women’s health therapeutics worldwide. As demand for hormone therapies continues to rise, pharmaceutical procurement teams increasingly require reliable intelligence on dydrogesterone buyers across global markets. This guide provides a structured overview of the dydrogesterone buyer landscape, covering key importers, regional demand patterns, regulatory considerations, and practical sourcing strategies for API and finished-dosage forms.

Understanding the Dydrogesterone Trade Landscape

The global dydrogesterone market has demonstrated consistent growth, driven by expanding applications in menstrual disorders, endometriosis, luteal phase support, and assisted reproductive technology. The pharmaceutical-grade dydrogesterone market was valued at USD 172 million in 2025 and is projected to reach USD 230 million by 2034, exhibiting a CAGR of 4.3%. The broader dydrogesterone drug market reached approximately USD 948 million in 2024 and is forecast to exceed USD 1.2 billion by 2031.

Trade flow analysis reveals that China leads global exports with a 39.86% share, while Bangladesh dominates imports with a 33.74% share. This concentration highlights the importance of understanding regional buyer profiles for effective procurement planning.

Key Global Buyers by Region

Asia-Pacific: The Largest Consumption Market

Asia-Pacific represents the largest regional market for dydrogesterone, holding a 68% share of global consumption. This dominance is driven by a combination of large patient populations, expanding healthcare access, and a robust generic manufacturing ecosystem.

Bangladesh stands out as the single largest importing nation for dydrogesterone API. The country’s pharmaceutical sector includes numerous WHO-GMP certified manufacturers that produce dydrogesterone formulations for both domestic use and export. Notable Bangladeshi buyers and manufacturers include Popular Pharmaceuticals Ltd., Incepta Pharmaceuticals Ltd., Renata Limited, Square Pharmaceuticals PLC, Eskayef Bangladesh Ltd., and Nuvista Pharma Ltd.. These companies actively import dydrogesterone API from suppliers in China and India to support their finished-dosage production.

India presents a dual profile as both a major producer and consumer of dydrogesterone. Indian pharmaceutical companies manufacture dydrogesterone API and formulations for domestic and international markets. Key Indian manufacturers and buyers include Mankind Pharma, Alkem Laboratories, Lupin Laboratories, Zydus Cadila Healthcare, and Jagsonpal Pharmaceuticals. Companies such as Taj Pharmaceuticals, Montage Laboratories, Cerata Pharmaceuticals, and Amber Lifesciences are actively engaged in dydrogesterone API and tablet exports, sourcing raw materials to meet production requirements.

China has emerged as a critical node in the dydrogesterone supply chain. Yangzhou Aurisco Pharmaceutical received the first generic approval for oral dydrogesterone in China, marking a significant milestone in the market. Other Chinese manufacturers and suppliers include Xian Guokang Ruijin Pharmaceutical, Hunan Keyixin Biopharmaceutical, and Zhejiang Xianju Pharmaceutical. These companies serve both domestic demand and export markets, particularly in Bangladesh and other Asian nations.

Europe: Established Market with Regulatory Sophistication

Europe accounts for approximately 15% of global dydrogesterone consumption, with Germany, France, the United Kingdom, Russia, and Italy representing the primary demand centers. The European market is characterized by stringent regulatory requirements and a preference for high-quality, GMP-certified API.

Abbott Healthcare Products B.V. in the Netherlands serves as a major manufacturer and supplier to European markets, producing dydrogesterone under the Duphaston brand. The company has received approvals in Russia and the Netherlands for dydrogesterone as the first oral treatment to prepare the uterus lining for in vitro fertilization. Binnopharm Group in Russia has launched Didromens (dydrogesterone) to address progesterone deficiency conditions, reflecting the ongoing localization of production within the region.

European buyers typically prioritize suppliers with EU-GMP certification, comprehensive documentation, and reliable supply chain transparency. The region’s regulatory framework demands rigorous pharmacovigilance and manufacturing consistency, influencing supplier selection criteria.

Middle East and Africa: Emerging Demand Centers

The Middle East and Africa region represents a growing market for dydrogesterone, with Saudi Arabia, UAE, Egypt, and South Africa among the key countries driving demand. Arasa Pharmaceuticals AG has been identified as a significant buyer in the Middle East, with substantial procurement volumes from Asian suppliers.

In North Africa, dydrogesterone is available across markets including Tunisia and Egypt, where Mylan and Solvay maintain distribution operations. South Africa similarly represents a notable market, with Abbott maintaining a presence in the region. These markets offer opportunities for suppliers capable of navigating diverse regulatory environments and establishing reliable distribution channels.

Latin America: A Market Poised for Growth

Latin America accounts for approximately 9% of global dydrogesterone consumption, with Brazil, Mexico, Argentina, and Colombia serving as the primary demand markets. The region’s pharmaceutical sector is characterized by a mix of multinational subsidiaries and local manufacturers, creating diverse procurement pathways.

Brazil represents the largest single market in Latin America for dydrogesterone, with consumption driven by both branded and generic formulations. Mexico similarly presents significant demand, supported by a well-developed healthcare infrastructure and growing awareness of women’s health issues.

Dydrogesterone API vs. Finished Dosage Buyers

Dydrogesterone buyers can be categorized into two primary groups: API buyers and finished-dosage buyers. Understanding the distinction is essential for effective market engagement.

API Buyers comprise pharmaceutical manufacturers that import dydrogesterone API to produce finished dosage forms such as tablets and capsules. These buyers typically require suppliers with GMP certification, comprehensive regulatory documentation (including DMF support), and consistent quality meeting pharmacopeial standards (USP, EP, or BP). The API market is characterized by long-term supply agreements and rigorous vendor qualification processes.

Finished Dosage Buyers include pharmaceutical distributors, hospital procurement departments, and retail pharmacy chains that purchase dydrogesterone tablets and capsules for direct patient use. These buyers prioritize product registration status, competitive pricing, and reliable delivery schedules. The finished dosage segment is increasingly influenced by generic competition and tender-based procurement in public healthcare systems.

Trade Codes and Documentation

Dydrogesterone is classified under HS Code 29372300, covering oestrogens and progestogens, with a specific subheading for dydrogesterone (dehydroprogesterone). Finished dydrogesterone formulations may fall under HS Code 30043900 or 3004390001, depending on the country’s tariff schedule and product presentation.

Proper documentation is critical for international dydrogesterone transactions. Buyers and sellers should ensure compliance with:

  • Certificate of Analysis (CoA) specifying assay, impurities, and physical characteristics
  • GMP certificates from recognized regulatory authorities
  • Drug Master File (DMF) or Certificate of Suitability (CEP) where applicable
  • Batch-specific documentation for traceability
  • Import licenses and product registration certificates for finished dosage forms

Regulatory Considerations for Buyers

Dydrogesterone’s regulatory status varies significantly across jurisdictions, influencing buyer behavior and market access.

In the United States, dydrogesterone was previously approved under NDA 017388 (GYNOREST) but was withdrawn from the market for commercial reasons. While not currently marketed in the US, the FDA has determined that the product was not withdrawn for safety or effectiveness reasons, which may facilitate future market entry under appropriate circumstances.

In Europe, dydrogesterone holds marketing authorizations in multiple countries, with Abbott Healthcare Products B.V. serving as a key marketing authorization holder. The product is approved in Russia and the Netherlands for luteal phase support in IVF, representing an expanded indication beyond traditional uses.

In Asia, dydrogesterone is widely approved and marketed, with significant generic penetration in India, Bangladesh, and China. Regulatory requirements vary by country, and buyers must ensure that suppliers possess the necessary documentation to support product registration in their respective markets.

Market Trends Influencing Buyer Behavior

Several trends are reshaping the dydrogesterone buyer landscape:

Rising demand for women’s health therapeutics is expanding the patient population eligible for dydrogesterone treatment. Increased awareness of conditions such as endometriosis, polycystic ovary syndrome, and infertility is driving diagnosis rates and treatment uptake globally.

Generic competition and price pressure are intensifying as more manufacturers enter the market. This trend benefits buyers by expanding supply options but requires rigorous supplier qualification to ensure quality and regulatory compliance.

Supply chain resilience has become a critical consideration following global disruptions. Buyers are increasingly diversifying supplier bases and prioritizing partners with robust logistics capabilities and transparent supply chains.

Digital health integration is influencing how dydrogesterone therapies are prescribed and dispensed. Telemedicine platforms and remote monitoring tools are creating new distribution channels and changing the dynamics of buyer-seller relationships.

Building an Effective Dydrogesterone Buyer Strategy

For procurement professionals seeking to engage with dydrogesterone buyers or expand their supplier network, several strategic considerations apply:

Verify regulatory compliance by confirming that suppliers hold valid GMP certifications, product registrations, and relevant pharmacopeial compliance documentation. Request batch-specific CoAs and audit manufacturing facilities where feasible.

Assess supply chain reliability through due diligence on supplier production capacity, lead times, and logistics partnerships. Consider dual-sourcing strategies to mitigate disruption risks.

Monitor market pricing through trade data platforms and industry benchmarks. API pricing can vary significantly based on order volume, purity specifications, and supplier origin.

Engage with industry networks through pharmaceutical trade exhibitions, sourcing platforms, and professional associations to identify new buyer and supplier opportunities.

Stay informed on regulatory developments in target markets, as changes in approval status or registration requirements can significantly impact market access and procurement strategies.

CHI NHÁNH CTY TNHH ZUELLIG PHARMA VIỆT NAM
KAUSTUBHA SCIENTIFIC RESEARCH LABORATORYPRIVATE LI
ABBOTT INDIA LIMITED
CHROMACHEMIE LABORATORY PRIVATE LIMITED
ABBOTT LABORATORIES PAKISTAN LIMITED
POPULAR PHARMACEUTICALS PLC
ООО PHARMAXI
MANKIND PHARMA LIMITED
MEDETHIX INC
OOO FARM LYUKS INVEST
ZYDUS HEALTHCARE LIMITED
ООО WHOLE PHARM
WEATHER FOLDS PHARMACEUTICALS
ООО CURATIO PHARM
ООО DRUG PROMOTION
NUVISTA PHARMA LTD
ООО GRAND PHARM TRADE
LLC GRAND PHARM TRADE
NABIQASIM INDUSTRIES PRIVATE LIMITED
RENATA PLC CHANGED FROM RENATA
NAARI PHARMA PRIVATE LIMITED
PHARMAXI
SAFFRON PHARMACEUTICALS PVT LTD
SKYWIN PHARMACEUTICALS
HEALTHCARE PHARMACEUTICALS LTD
WELMARK PHARMACEUTICALS
ABBOTT LABORATORIES PAKISTAN LTD
CINCHONA BIOSCIENCES
INCEPTA PHARMACEUTICALS LIMITED
NABIQASIM INDUSTRIES PVT LTD
SQUARE PHARMACEUTICALS PLC CHANGED
DYSON RESEARCH LABORATORIES PVT LTD
HETERO LABS LIMITED
M S PACIFIC PHARMACEUTICALS LTD
PACIFIC PHARMACEUTICALS LTD
SC VEROPHARM
ESKAYEF PHARMACEUTICALS LIMITED
UNITED STATES PHARMACOPEIA INDIA PRIVATE LIMITED
ZAFA PHARMACEUTICAL LABORATORIES PVT LIMITED
ACME FORMULATION PRIVATE LIMITED
ARIES PHARMACEUTICAL PRIVATE LIMITED
DRUG PROMOTION
ELCON DRUGS AND FORMULATIONS LIMITED
RENATA LTD CHANGE FROM PFIZER
RIFA PHARMA
THE ACME LABORATORIES LIMITED
ABBOTT LABORATUARLARI ITHALAT IHRACAT VE TICARET LIMITED SIRKETI
AKUMS DRUGS AND PHARMACEUTICALS LIMITED
ANALYTICA CHEMIE INC
JAVED CHEMICAL CORPORATION
LLOYD LABORATORIES INC
M S LAHORE CHEMICAL PHARMACEUTICAL WORKS PVT LTD
M S PHARMA HEALTH PAKISTAN PVT LTD
M S WELWRD PHARMACEUTICAL
M S WNSFEILD PHARMACEUTICALS
M S WNSFIELD PHARMACEUTICLS
OOO MEROS PHARM
SKYWIN PHARMACEUTICALS PRIVATE LIMITED
ULTRA INTERNATIONAL
AERO PHARM GROUP
BHARAT SERUMS AND VACCINES LIMITED
GRAND PHARM TRADE
LLC PHARMAXI
M S ABBOTT LABORATORIES PAK LTD
OOO GRAND PHARM TRADE
PHARMARAW BANGLADESH PRB
POPULAR PHARMACEUTICALS LTD
SIMSON PHARMA LIMITED
SKYWIN PHARMACEUTICALS PVT LTD
SUCOPEIA REFERENCESTANDARDS OPC PRIVATE LIMITED
TAREQUE ENTERPRISE
ARIES PHARMACEUTICAL PVT LTD
CÔNG TY CỔ PHẦN KHOA HỌC CÔNG NGHỆ T T
CÔNG TY TNHH DỊCH VỤ THƯƠNG MẠI PHẠM NGUYỄN
FARM LYUKS INVEST
NUVISTA PHARMA PLC CHANGED FROM
PHARMA HEALTH PAKISTAN PVT LTD
SABIHA RESEARCH AND DEVELOPMENT LLP
WINBRAINS RESEARCH LABORATORIES
WNSFEILD PHARMACEUTICALS
ABBOTT LABORATORIES PAK LTD
CÔNG TY TNHH DRP INTER
EFROZE CHEMICAL INDUSTRIES PRIVATE LTD
GENOME PHARMACEUTICALS PVT LIMITED
GENOME PHARMACEUTICALS PVT LTD
GERRY S INTERNATIONAL PRIVATE LIMITED
JSC MEROS PHARM
KAUSTUBHA SCIENTIFIC RESEARCH LABORATORY PRIVATE L
KAUSTUBHA SCIENTIFIC RESEARCH LABORATORY PRIVATE LIMITED
LLC AERO PHARM GROUP
LLC CURATIO PHARM
LLC DRUG PROMOTION
M S ABBOTT LABORATORIES PAKISTAN LTD
NABI QASIM INDUSTRIES PRIVATE LIMITED
OBS PHARMA PRIVATE LIMITED
OMSYNTH LIFESCIENCES PRIVATE LIMITED
ROYAL PHARMA 2011 LIMITED
SAMI PHARMACEUTICALS PVT LIMITED
SAMI PHARMACEUTICALS PVT LTD
ULTRA BIO INSTRUMENTS PRIVATE LIMITED
WHOLE PHARM
ZAFA PHARMACEUTICAL LABORATORIES PRIVATE LIMITED
ZAFA PHARMACEUTICAL LABORATORIES PVT LTD
ZISKA PHARMACEUTICALSLIMITED
ТОО GENERAL PHARMA
AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED
AJANTA PHARMA LIMITED
ALEMBIC PHARMACEUTICALS LIMITED
ALEMBIC PHARMACEUTICALS LTD
ANNORA PHARMA PRIVATE LIMITED
ARIES PHARMACEUTICALS PVT LTD
ATLANTIC GOODS DISTRIBUTION LLC
CHEMX TREE STANDARDS
CORONA REMEDIES LIMITED
CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX
CÔNG TY TNHH SẢN XUẤT NAVIS VIỆT NAM
EFROZE CHEMICAL INDUSTRIES PVT LTD
EMERALD ENTERPRISES
FREDMANN PHARMACEUTICALS PVT LTD
GALAXY PHARMACEUTICAL LIMITED
GENTRY CORPORATION LIMITED
INTERLAB LABORATUAR URUNLERI SANAYI VE TICARET ANONIM SIRKETI
JSC FARM LYUKS INVEST
JSC GRAND PHARM TRADE
LAHORE CHEMICAL PHARMACEUTICAL WORKS PVT LTD
LLC WHOLE PHARM
M S WEATHER FOLDS PHARMACEUTICALS
M S WELWRD PHARMACEUTICALS
MARTIN DOW SPECIALITIES PRIVATE LIMITED
MED COMPANION LIMITED
MEDCURE HEALTHCARE LTD
NOVELL PHARMACEUTICAL LABORATORIES
PLATINUM PHARMACEUTICALS PRIVATE LIMITED
REPRICO S A
STABICON LIFE SCIENCES PRIVATE LIMITED
TROIKAA PHARMACEUTICALS LIMITED
WELWRD PHARMACEUTICAL
WELWRD PHARMACEUTICALS
WOLONG SOKO INDONESIA
ZYDUS LIFESCIENCES LIMITED
АТ ФАРМАК УКРАЇНА 04080 М КИЇВ ВУЛ КИРИЛІВСЬКА 63
ООО HURSHIDA ENTER DELUX
ООО MEROS PHARM
ТОВ БУСТ ФАРМА 03022 КИЇВ В ВАСИЛЬКІВСЬКА Б 30
ABBOTT HEALTHCARE PRIVATE LIMITED
AGP LIMITED
ASPIN PHARMA PVT LIMITED
ASPIN PHARMA PVT LTD
BIOCKRODT PHARMA
BIOORGANICS AND APPLIED MATERIALS PRIVATE LIMITED
CLEARSYNTH LABS LIMITED
CÔNG TY CỔ PHẦN ASTA HEALTHCARE USA
CÔNG TY CỔ PHẦN DƯỢC PHẨM TRƯỜNG THỌ
CÔNG TY CỔ PHẦN HÓA DƯỢC VIỆT NAM
CÔNG TY TNHH VẬT TƯ KHOA HỌC CÔNG NGHỆ T T
DHL KEELLS PVT LTD
DHL PAKISTAN PRIVATE LIMITED
DRUGLAND CORPORATION
DYSON RESEARCH LABORATORIES
DYSON RESEARCH LABORATORIES PVT L
EFROZE CHEMICAL INDUSTRIES PRIVATE LIMITED
EMCURE PHARMACEUTICALS LIMITED
EMCURE PHARMACEUTICALS LTD
FARMINDUSTRIA S A
FREDMANN PHARMACEUTICALS
FREDMANN PHARMACEUTICALS PRIVATE LIMITED
G2 PHARMACY
GUTIS LIMITADA
GYNOPHARM SOCIEDAD ANONIMA
HANSEL PHARMACEUTICALS PVT LTD
HEALTH CARE PRODUCTS
HELM DE MEXICO SA
HIGHNOON LABORATORIES LIMITED
INTEGRATED BIOSCIENCES
KARUNIA JASINDO
LAHORE CHEMICAL PHARMACEUTICALS WORKS
LAHORE CHEMICAL PHARMACEUTICALS WORKS PV
LIBRA PRIVATE LIMITED
LLC MEROS PHARM
M S ABBOTT LABORATORIES PAKISTAN LIMITED
M S FREDMANN PHARMACEUTICALS PVT LTD
M S HIGHNOON LABORATORIES LTD
M S J K ENTERPRISES
M S MUSAJI ADAM SONS
MASS PHARMA PVT LIMITED
MERRYMED FARM
MOLECULES ANALYTICAL LAB SOLUTIONS PRIVATE LIMITED
MR RIAZ ILYAS
NABIQASIM INDUSTRIES PVT LIMITED
NATIONAL PHARMACY LIMITED
OH INNOLEK
PHARMAFFILIATES ANALYTICS AND SYNTHETICS PRIVATE L
PHARMAFFILIATES PRIVATE LIMITED
PHARMATECH BOLIVIANA S A
PHILLIPS PHARMACEUTICALS TANZANIA LIMITED
PHRMA HEALTH PAKISTAN PVT LTD
PLATINUM PHARMACEUTICAL PRIVATE LIMITED
PLATINUM PHARMACEUTICALS PVT LIMITED
PRASI LABS PRIVATE LIMITED
PT DEXA MEDICA
PT IMCD INDONESIA
PT MERCK CHEMICALS LIFE SCIENCES
PT PRATAPA NIRMALA
PT SRI AMAN CORPORINDO
SIGMA ALDRICH CHEMICALS PRIVATE LIMITED
SKYWIN PHARMACEUTICALS LTD
STAR TRADING CORPORATION
STERIL GENE LIFE SCIENCES PRIVATE LIMITED
SYMBIO GENERRICS INDIA PRIVATE LIMITED
SYNOKEM PHARMACEUTICALS LIMITED
TECHNOKIT CORPORATION
UNIMED UNIHEALTH PHARMACEUTICALS
UNISEL LIMITED
WEATHERFOLDS PHARMACEUTICALS
WELWINK PHARMACEUTICALS
WESTCOAST PHARMACEUTICAL WORKS LIMITED
WNSFIELD PHARMACEUTICALS
ZAFA PHARMACEUTICAL LABORATORIES
ГУ ЦЕНТР БЕЗОПАСНОСТИ ФАРМАЦЕВТИЧЕСКОЙ ПРОДУКЦИИ
ИП ООО ACWA POWER DZHANKELDY WIND
ИП ООО KDV UZB
ИП ООО PORTAKAL
ИП ООО БЭЛТОН ТРЕЙДИНГ АЗИЯ
ООО PHARM SPECTR
ТОВ ІНСТИТУТ БІОХІМІЧНИХ ТЕХНОЛОГІЙ 03179 М КИЇВ ПР ПЕРЕМОГИ 123
ТОВАРИСТВО З ОБМЕЖЕНОЮ ВІДПОВІДАЛЬНІСТЮ ІНЕСЕНЛАБС УКРАЇНА 07302 КИЇВСЬКА ОБЛ ВИШГОРОДСЬКИЙ Р Н МІСТО ВИШГОРОД ВУЛ

Conclusion

The global dydrogesterone market presents diverse opportunities for buyers and suppliers across Asia-Pacific, Europe, the Middle East, Africa, and Latin America. Understanding regional buyer profiles, regulatory landscapes, and supply chain dynamics is essential for effective procurement and market participation. By leveraging the insights in this guide and maintaining rigorous quality and compliance standards, pharmaceutical professionals can navigate the dydrogesterone trade landscape with confidence.

error: Content is protected !!